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followed from the date of breast cancer diagnosis through death or December 31,
2009. Patients were identified as having positive (negative) ER or PR status if the
corresponding assay was reported to SEER as positive/elevated (negative/normal).
Demographics, initial treatment (surgery or radiation within 4 months of diagno-
sis), and survival (Kaplan-Meier [KM] survival curves) were evaluated, by ER and PR
status. RESULTS:A total of 3210 female Stage IV BC patients (2,417 [75.3%] ER, and
793 [24.7%] ER-) were identified. Of these, 57.5% were ERPR, 17.8% were ERPR-,
1.4% were ER-PR, and 23.3% were ER-PR-. Age at diagnosis was similar regardless
of ER/PR status (mean [SD] 74-77 [6-7] years). Almost one third of patients had
radiation (30%) and close to half of patients had surgery (43%) in the first 4 months
following diagnosis, with slight variation by ER/PR status. KM survival analyses
suggest that ER patients had significantly higher median survival than ER- pa-
tients (24 months vs. 9 months, P0.01). Median survival was highest for ERPR
patients (25 months) followed by ERPR- (19 months), ER-PR- (9 months), and ER-
PR (7 months). CONCLUSIONS: Among elderly, newly diagnosed Stage IV BC pa-
tients, those with ERPR status had the best survival outcomes. Further studies
of treatment patterns and outcomes by ER and PR status are warranted.
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OBJECTIVES:Although breast cancer is the most common cancer among American
women, study investigating treatment pattern and costs is limited. This study aims
to determine breast cancer treatment patterns and associated health care charges
stratified by initial stage at diagnosis. METHODS: Patients were retrieved from the
University of Utah Huntsman Cancer Institute (HCI) and the Utah Population Da-
tabase. We included female patients with age 18, having 1of breast cancer
ICD9-CM codes, providing informative staging data, and with2 encounters during
the time period. Matching to the HCI Tumor Registry using ICD-0 histology and site
codes validated a primary site breast cancer. Treatment patterns, health care
charges, and overall survival were evaluated. RESULTS:Of 495,523 female patients,
3,109 breast cancers were identified. Mean age was 59.9, 54.6, 53.7, and 56.2 years at
stage I (n1,310), II (n1,220), III (n425), and IV (n154), respectively. The mean
Charlson co-morbidity score (p0.001), the distribution of age (p0.001) and insur-
ance plan types (p0.001) were all significant between the stage groups. Patients
diagnosed at stage I, II, and III received surgery as first treatment, then radiation,
and chemotherapy. Stage IV patients had the highest proportion of patients utiliz-
ing chemotherapy as first treatment, followed decreasing utilization by stages III, II,
and I. The largest annualized charges were incurred in stage IV patients ($68,227),
followed by decreasing charges by stage III ($38,178), II ($23,214), and I ($14,615).
Five year overall survival was 91.15%, 84.43%, 71.76%, and 35.06% for stage I, II, III,
and IV patients, respectively. CONCLUSIONS: Data suggests that our cohort was
generally treated according to NCCN guidelines. Charges increased by stage. Sur-
vival rates decreased by stage and were higher than National Cancer Data Base
statistics. These results provide unique information on the utilization and treat-
ments in breast cancer towards the further conduct of oncology outcomes re-
search.
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OBJECTIVES: Ovarian cancer is the fifth most common cause of cancer death in
women; therefore study investigating treatment patterns, heath care charges and
overall survival is warranted. This study aims to determine ovarian cancer treat-
ment pattern and charges stratified by initial diagnosis stages.METHODS: Patients
were retrieved from linking records in the University of Utah Enterprise Data Ware-
house, the Utah population database, and the Huntsman Cancer Institute Tumor
Registry. We included female patients with age18, having one or more of ovarian
cancer ICD9-CM code (183.0), with informative staging data, and at least 2 encoun-
ters during 1995 to 2010. Treatment patterns, health care charges, and survival
were stratified by stage at initial diagnosis. RESULTS: Of 495,523 female patients,
379 ovarian cancers were identified. Mean age was 51.9, 54.1, 59.3, and 63.5 years at
stage I (n83), II (n31), III (n176), and IV (n89), respectively (p0.001). The mean
Charlson co-morbidity score was significant between the stage groups (p0.001) as
was the distribution of age groups (p0.004). Patients received surgery as first treat-
ment, then chemotherapy, and radiation in all stages. The largest annualized
charges were incurred in stage IV patients ($72,579), followed in decreasing charge
magnitude by stage III ($48,765), II ($50,303), and I ($29,479), respectively. Five year
overall survival was 81.93%, 77.42%, 49.43%, and 15.73% for stage I, II, III, and IV
patients, respectively. CONCLUSIONS: Our findings show that the treatment and
time to treatment in our cohorts mostly follow NCCN guidelines. Patients present-
ing in later stages, as expected, experience reduced survival and increased health
care charges. These results provide unique information on the utilization and
treatments in ovarian cancer towards the further conduct of oncology outcomes
research or economic evaluation. Further study identifying predictors of long term
survival and reduced resource utilization is needed.
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OBJECTIVES: Since the incidence rate of melanoma has more than doubled in the
past 30 years, study investigating treatment patterns and health care charges and
overall survival is warranted. This retrospective study aims to determine mela-
noma treatment patterns, charges, and overall survival stratified by initial stage at
diagnosis. METHODS: Patients were retrieved from linking records in the Univer-
sity of Utah Enterprise Data Warehouse, the Utah Population Database, and the
Huntsman Cancer Institute Tumor Registry during 1995-2010. We included pa-
tients with age 18; having one or more of melanoma ICD9-CM codes; melanoma
associated ICD-0 histology/site codes from the HCI tumor registry with informative
staging data; and had at least 2 encounters during the time period. Treatment
pattern, health care charges and survival were stratified by stage at initial
diagnosis. RESULTS: Of 965,460 patients, 1,463 melanoma patients were identified.
At the time of diagnosis 829 subjects were considered stage I; 254 stage II; 289 stage
III; and 91 stage IV. . The mean Charlson comorbidity score was significantly in-
creased according to the stage group (p0.001) of the patient. Patients diagnosed at
stage I, II, and III received radiation as first treatment, then surgery, followed by
chemotherapy. The most common first treatment for patients with stage IV disease
was chemotherapy. The highest annualized cancer related charges per year, based
on survival days, were incurred by stage IV patients ($80,396), followed by stage III
($33,268), stage II ($21,397), and stage I ($8,327). Five year overall survival rate was
91.44%, 72.44%, 61.59%, and 34.07% for stage I, II, III, and IV patients, respectively.
CONCLUSIONS: This study highlights the distinctive advantages in utilizing com-
prehensive electronic health records by combining in depth clinical data and out-
comes with health care charges, which can be used to assess the cost-effectiveness
of the newly developed melanoma therapeutics.
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OBJECTIVES: The surrogacy of progression-free survival (PFS) for overall survival
(OS) remains a matter of uncertainty in metastatic breast cancer (mBC). Therefore,
the aim of this study was to assess the relationship between PFS and OS in mBC
using a trial-based approach. METHODS: A systematic literature review was per-
formed using the PICO method: Population consisted of women with mBC; Inter-
ventions and Comparators were standard treatments for mBC or best supportive
care; Outcomes of interest were median PFS or TTP and median OS. A correlation
analysis between median PFS and OS was first performed and subgroup analyses
were conducted to explore possible reasons for heterogeneity. Then, the relation-
ship between the treatment effect on PFS and OS was assessed. The treatment
effect on PFS and OS was quantified by the absolute difference of median values.
Linear regression analysis was also conducted to predict the effects of a new anti-
cancer drug on OS on the basis of its effects on PFS. RESULTS: In total, 5041 studies
were identified and 144 fulfilled the eligibility criteria. There was a significant re-
lationship between median PFS and median OS across included trials (r0.428;
p0.01). The correlation coefficient for the treatment effect on PFS and OS was
estimated at 0.427 (p0.01). The linear regression equation was: 	OS -0.088 (95%
CI, -1.347 to 1.172)  1.753 (95% CI, 1.307 to 2.198) * 	PFS, with a proportion of
variation explained (R2) of 0.86. Results of the regression analysis predict that a
difference in median PFS of 5, 10, 15, and 20 months would translate into a differ-
ence in median OS of 8.7, 17.4, 26.2, and 35.0 months respectively. CONCLUSIONS:
The present findings point toward a statistically significant correlation between
PFS and OS in the context of mBC and support the surrogacy of PFS for OS in this
cancer setting.
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OBJECTIVES: Surrogate endpoints, such as progression-free survival (PFS) and
time-to-progression (TTP), are frequently used to evaluate the clinical benefits of
new anticancer drugs. However, the surrogacy of these endpoints for overall sur-
vival (OS) is not validated in all cancer settings. The main objective of this study
was to evaluate the relationship between median PFS/TTP and median OS in the
context of chronic lymphocytic leukemia (CLL) using a trial-based approach.
METHODS: A systematic review of the literature was conducted using the PICO
method: Population consisted of patients with CLL; Interventions and Comparators
(when applicable) were standard therapies for CLL and Outcomes were median
PFS/TTP and median OS. Two independent reviewers screened titles, abstracts,
and full papers for eligibility, and then extracted data from selected studies. Cor-
relation coefficient was calculated to assess the relationship between median PFS/
TTP and median OS. Subgroup correlation analyses were also conducted according
to characteristics of selected studies such as line of treatment and type of treat-
ment under investigation. RESULTS: Among the 1,263 potentially relevant studies
identified by the literature search, 23 articles were included. The mean number of
A414 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
